P1.04-03 Independent Validation of the Maisonneuve Lung Cancer Risk Model to Optimize Screening Interval in High-risk Individuals

MLA

P. Maisonneuve, et al. “P1.04-03 Independent Validation of the Maisonneuve Lung Cancer Risk Model to Optimize Screening Interval in High-Risk Individuals.” Journal of Thoracic Oncology, vol. 17, Sept. 2022, p. S102. EBSCOhost, https://doi.org/10.1016/j.jtho.2022.07.169.

APA

P. Maisonneuve, M. Casiraghi, R. Bertolotti, C. Rampinelli, P. Muriana, L. Spaggiari, & G. Veronesi. (2022). P1.04-03 Independent Validation of the Maisonneuve Lung Cancer Risk Model to Optimize Screening Interval in High-risk Individuals. Journal of Thoracic Oncology, 17, S102. https://doi.org/10.1016/j.jtho.2022.07.169

Chicago

P. Maisonneuve, M. Casiraghi, R. Bertolotti, C. Rampinelli, P. Muriana, L. Spaggiari, and G. Veronesi. 2022. “P1.04-03 Independent Validation of the Maisonneuve Lung Cancer Risk Model to Optimize Screening Interval in High-Risk Individuals.” Journal of Thoracic Oncology 17 (September): S102. doi:10.1016/j.jtho.2022.07.169.